Jesús Herrero‐Garibi

Jesús Herrero‐Garibi

Auto-generated profile, based on publicly available information

Jesús Herrero‐Garibi

Department of Cardiology Complejo asistencial universitario de Salamanca (CAUSA) Salamanca Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
SLSergio López-Tejero
Sergio López-Tejero
Pablo Jose Antunez-MuiñosPablo Jose Antunez-Muiños
Pablo Jose Antunez-Muiños
PFPilar Fraile‐Gómez
Pilar Fraile‐Gómez
GSGilles Barreira‐De Sousa
Gilles Barreira‐De Sousa
JRJavier Rodríguez‐Collado
Javier Rodríguez‐Collado
ICIgnacio Cruz‐González
Ignacio Cruz‐González
Introduction and Objectives: Advanced chronic kidney disease (A‐CKD) combined with atrial fibrillation increases the risk of both thrombogenic and bleeding events. Left atrial appendage occlusion (LAAO) may be an alternative to oral anticoagulation to prevent thromboembolic events. We aimed to evaluate the outcomes of LAAO in patients with A‐CKD.Methods: Comparison at long‐term follow‐up of patients diagnosed with and without A‐CKD (eGFR<30 mL/min/1.73 m2) who underwent LAAO between 2009 and May 2022.Results: Five hundred seventy‐three patients were included. Eighty‐one (14%) were diagnosed with A‐CKD. There were no differences in sex, age, and cardiovascular risk factors, except for diabetes which was more frequent in patients with A‐CKD. The control group had higher rates of stroke, both ischemic and hemorrhagic. There were no differences in the CHA2DS2‐VASc score, although A‐CKD patients had a higher bleeding risk according to the HASBLED scale. Global procedural success was 99.1%. At follow‐up, there were no differences in stroke rate: at 1‐year (HR: 1.22, IC‐95%: 0.14–10.42, p = 0.861); at 5‐years (HR: 0.60, IC‐95%: 0.08–4.58, p = 0.594). Although bleeding events were higher in the A‐CKD group, no differences were found in major bleeding (defined BARC ≥ 3) at 1‐year (HR: 1.34, IC‐95%: 0.63–2.88, p = 0.464) or at 5‐years follow‐up (HR: 1.30, IC‐95%: 0.69–2.48, p = 0.434). Mortality rate at 5 years was higher in the A‐CKD patients (HR: 1.84, IC‐95%: 1.18–2.87, p = 0.012).Conclusions: LAAO is an effective and safe treatment in A‐CKD patients to prevent ischemic events and bleeding. This strategy could be an alternative to oral anticoagulation in this high‐risk group of patients.

16 June 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
EBEyal Ben‐Assa
Eyal Ben‐Assa
JHJesús Herrero‐Garibi
Jesús Herrero‐Garibi
ICIgnacio Cruz-Gonzalez
Ignacio Cruz-Gonzalez
SESammy Elmariah
Sammy Elmariah
PRPablo Rengifo‐Moreno
Pablo Rengifo‐Moreno
IPIgor F. Palacios
Igor F. Palacios